Skip to content
EmergingResearch compoundReference only

Phenylpiracetam Hydrazide

Experimental research chemical related to phenylpiracetam: studied only in rodents, with essentially no human data.

NootropicRacetamResearch chemicalRacetamPhenylpiracetamHydrazideDopamineGlutamateAcetylcholine

Pharmacology

ClassRacetam · Phenylpiracetam · Hydrazide
Primary targetRacetam pyrrolidinone core; presumed cholinergic and glutamatergic modulation (parent-inferred DAT inhibition)
Targets3 receptor targets
Half-lifeN/A (no PK data)
OnsetN/A (no established protocol)
EvidenceReference only
Affected systemsDopamineGlutamateAcetylcholine

Contents

DETAILED OVERVIEW

What is Phenylpiracetam Hydrazide?

Phenylpiracetam hydrazide is an experimental research chemical, a chemically modified relative of phenylpiracetam (also called fonturacetam). It was first described in 1980, when Russian researchers were studying compounds against seizures. It is not an approved medicine anywhere; it is sold as a research chemical, often labeled “not for human consumption”.

In rodents, in a model of seizures triggered by electric current, it showed an anti-seizure effect. It has not been tested in humans, and its supposed effects on focus, alertness and stress tolerance are inferred from phenylpiracetam, not measured. Its safety profile is unknown, and as a research chemical, contamination and mislabeling are real risks. There are no safety data for pregnancy and breastfeeding, so it should be avoided. Phenylpiracetam is a banned doping agent, so this relative may also be risky for competitive athletes, as it could fall under the rule on similarly structured substances.

Mechanism

Hydrazide analog of phenylpiracetam (parent-inferred)

Half-life

N/A (no PK data)

Legal status

Research chemical, not approved

Evidence

Reference-only (no human trials)

Receptor profile

  • Racetam pyrrolidinone core (presumed cholinergic/glutamatergic)Weak
  • Dopamine transporter (DAT), inferred from parentWeak
  • Seizure threshold / anticonvulsant activity (animal model)Weak

Safety

Side effects, stop signs, contraindications

Side effects · 5

  • Overstimulation, irritability and insomnia, as a presumed class effect (not measured)
  • Headache, commonly associated with racetams, may relate to choline depletion
  • Unknown safety profile: no dedicated human toxicology or adverse-effect data exist
  • Unpredictable purity: as a research chemical, contamination and mislabeling are real risks
  • Anecdotal reports describe effects as often subtle or minimal, which may tempt higher, riskier dosing

Contraindications · 5

  • Pregnancy and breastfeeding: no safety data, should be avoided
  • Human consumption in general: not an approved medicine, intended for research use only
  • Hepatic or renal impairment: unknown metabolism and clearance, caution
  • Competitive athletes: the parent is WADA-prohibited and the analog may fall under the similar-structure clause
  • Epilepsy / seizure threshold: although anticonvulsant in animals, uncharacterized in humans, medical supervision advised

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

This is a purely experimental research chemical with essentially no human data of its own: everything it's supposedly good for (focus, alertness, stress resilience) is just inferred from a related compound, phenylpiracetam, not actually proven for this substance. The only real measurements come from animal studies (an anticonvulsant effect in mice), so there's practically no reliable knowledge about using it in people.

Telegram

Have a question about Phenylpiracetam Hydrazide?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC12H15N3O2
UpdatedOctober 12, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 12, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.